Top Injectable Manufacturer in Costa Rica – Reliable Pharmaceutical Solutions
- Maulik Sudani
- 5 hours ago
- 10 min read
Last Updated: August 26, 2026
TL;DR: Costa Rica has two gates, and most first-time exporters only plan for the first one. The Ministerio de Salud grants the sanitary registration that makes your injectable legal to sell – filed on the Registrelo platform, valid for five years, under the Central American technical regulation RTCA 11.03.59, and requiring an apostilled certificate of pharmaceutical product or GMP certificate plus a locally domiciled legal representative. The second gate is the one that decides whether you ever have a customer: the Caja Costarricense de Seguro Social, which will spend around US$506 million on medicines in 2026, will not buy a product that has not passed its own technical prequalification, in which its laboratory physically tests a sample of your vial against its own ficha tecnica and the USP and BP general chapters. Farbe Firma Pvt Ltd fills sterile injectables on ISO Class 5 aseptic lines in a WHO-GMP certified facility in Gujarat, India, and builds the analytical, stability and documentation package a Costa Rican importer needs to clear both.
Key Takeaways
Registration and procurement are two separate, sequential hurdles. A sanitary registration from the Ministerio de Salud makes an injectable legal in Costa Rica; it does not make it purchasable by the public system. The Caja Costarricense de Seguro Social operates its own Precalificacion Tecnica de Medicamentos, and a product that is not prequalified cannot be offered into a CCSS tender no matter how impeccable its Ministry file is. Any commercial plan for Costa Rica that budgets time and documentation for only the first gate is a plan that will stall halfway.
The CCSS prequalification is an analytical test, not a paperwork review. The supplier delivers documents and a physical product sample to the Laboratorio de Normas y Calidad de Medicamentos, and the sample is tested against the analytical monograph in the CCSS ficha tecnica, against the manufacturer's own declared specification, or against what the Ministerio de Salud approved, together with USP and BP general chapters. Three or fewer non-conformities buy you one correction window of ten working days. More than three, a missed deadline, or any non-conformity that requires a root-cause investigation at the factory produces a No Conforme report and the whole prequalification restarts from zero with a new sample. First-pass analytical conformity is therefore the entire commercial argument.
The ICH homologation shortcut is dead, and a lot of published advice has not caught up. Executive Decree 43590-S, which promised recognition of registrations granted by ICH member authorities on a sworn declaration, was declared unconstitutional by Costa Rica's Sala Constitucional in judgment 2024-21860 in August 2024, with retroactive effect. What survives is narrower and different: reliance under Decree 39433-S, as reformed, on the evaluation of clinical and non-clinical study reports by recognised reference regulatory authorities, a list the Ministry expanded from nine to thirty-five in November 2023. Plan for the full route, not the shortcut.
Costa Rica is a life-sciences manufacturing power that does not make its own injectables. Medical and precision devices accounted for around 43% of the country's total exports in 2024, approaching US$9 billion, with roughly a hundred device companies operating largely from free trade zones. That capability sits in devices, not in sterile parenterals, which are imported. An Indian sterile injectable manufacturer is therefore selling into a sophisticated, quality-literate buying culture that has no domestic competitor in the category – a combination that rewards technical credibility far more than a low quote.
Introduction: Why Costa Rica Demands a Premium Injectable Manufacturer in Costa Rica
Costa Rica is a small market that behaves like a much larger one, and the reason is concentration. Medicines are registered by the Ministerio de Salud, whose registration resolutions are issued under the DRPIS reference, and the registration is filed virtually through the Registrelo platform at registrelo.go.cr with a validity of five years. The substantive requirements come from the Central American technical regulation on sanitary registration of medicines for human use, RTCA 11.03.59, adopted into Costa Rican law by executive decree, with separate national instruments covering bioequivalence, biological products, therapeutic equivalence and stability studies. In practice a foreign manufacturer files through a legal representative domiciled in Costa Rica, appointed by a notarised and apostilled power of attorney, alongside a responsible professional, and the import itself runs through a Ministry-registered drogueria.
What the registration does not do is sell anything. Roughly nine in ten Costa Ricans are covered by the Caja Costarricense de Seguro Social, and the CCSS is the buyer that matters. Its logistics management has stated that the institution will spend about 228 billion colones, close to US$506 million, on medicines in 2026. Its published account of spending in 2022 records more than US$320 million on medicines, over US$34 million on hypertension, diabetes and cardiovascular disease for more than a million people, and about US$84 million on cancer and immunological disease for roughly thirty thousand patients, with thirty-four high-cost medicines alone accounting for US$60.2 million. Choosing an injectable manufacturer in Costa Rica's supply chain therefore means choosing one that can satisfy a national regulator and a demanding institutional laboratory in the same submission cycle.
What Sets a World-Class Injectable Manufacturer in Costa Rica Apart
The first differentiator is being current about what the law actually is. A great deal of published guidance still tells exporters that Costa Rica homologates registrations from ICH member authorities in thirty business days on a sworn declaration. That decree, 43590-S, was struck down by the Sala Constitucional in judgment 2024-21860 in August 2024, with declarative and retroactive effect, on grounds that included the absence of an adequate administrative procedure and the absence of prior consultation. What remains in force is reliance under Decree 39433-S, as reformed, on the evaluation and approval of clinical and non-clinical study reports by reference regulatory authorities, a list the Ministry expanded from nine to thirty-five authorities by resolution published in November 2023, with the reformed technical criterion keyed to the World Health Organization's listed-authority framework. That is a narrower instrument and it is not a shortcut to registration. A supplier who tells you otherwise is quoting a dead decree.
The second is a realistic view of timing. The most careful cross-country assessment available, the technical-barriers study prepared for the European Commission's trade directorate and published in August 2023, describes the Costa Rican sequence as registration of the power of attorney at the Ministry taking two to three months, then examination running six to twelve months, with objections answered within ten days and a limited ability to query the examiner, and it puts the overall duration at twelve to eighteen months while noting plainly that Costa Rica is one of the slowest approvers in the region. The same study records that mutual recognition of Central American registrations exists on paper in the RTCA but that each authority still evaluates according to national law, and that there is no true harmonisation in how the regional rules are interpreted. A registration granted in Guatemala or Panama is not a passport into Costa Rica, and a partner who plans on that assumption will lose a year.
Quality Systems Behind Every Sterile Injectable
Farbe Firma fills sterile injectables on ISO Class 5 aseptic lines inside a WHO-GMP certified facility in Gujarat, India. Sterility assurance is designed into the process rather than inferred from a final test: terminal sterilisation or aseptic processing is chosen on the product's own merits and supported by media fill validation, routine environmental and personnel monitoring, container closure integrity testing and a documented contamination control strategy. Release testing runs on HPLC and GC for assay and related substances, LAL for bacterial endotoxins, Karl Fischer for water content where the presentation calls for it, and full compendial sterility testing. Because a Costa Rican sample will be tested against USP and BP general chapters at the CCSS laboratory, the compendial reference set matters more here than in most markets, and ours covers IP, USP, BP and EP with the method transfer and validation records to support whichever monograph a reviewer selects.
Stability is generated to ICH Q1A(R2) with photostability under ICH Q1B, in the container-closure system that will actually ship, and defended on hot and humid conditions rather than temperate ones. Costa Rica is comparatively pragmatic here: it accepts stability data generated on pilot and development batches manufactured at development sites, which is more flexible than several other Latin American regimes, but the data still has to survive a technical read. Dossiers are compiled in CTD structure, which remains the most portable starting point for a Central American filing, and every certificate that will need to travel through notarisation and apostille – the certificate of pharmaceutical product, the GMP certificate, the manufacturing contract where a third party conditions the product – is issued in a form that survives that chain without a reissue. Spanish-language artwork and inserts are prepared for primary and secondary packaging, in editable form, so an importer can answer an artwork query without waiting on a new production cycle.
Looking for a sterile injectable manufacturing partner? Submit a Quick Inquiry
Why Farbe Firma is the Trusted Injectable Manufacturer in Costa Rica for Global Buyers
The commercially decisive point about Costa Rica is that the buying decision is a laboratory decision. Prequalification requests to the CCSS are made by email on Thursdays and appointments notified on Fridays, evaluated in order of arrival, and the supplier then physically delivers the documentation and a product sample to the Laboratorio de Normas y Calidad de Medicamentos, with separate files for biological, biotechnological, antineoplastic and bioequivalence-dependent products assessed by the Direccion de Farmacoepidemiologia. Technical prequalification or renewal is decided within a maximum of fifty-five calendar days and updates within fifteen, with any formal query restarting the clock. Prequalification is suspended if the Ministry annuls the underlying sanitary registration, if the supplier fails to update after a change to the ficha tecnica, or if product arrives at the CCSS storage and distribution area twice in two consecutive years with characteristics different from those declared and approved. Read together, those rules reward exactly one thing: a manufacturer whose batches match their own paperwork, every time.
India is already a meaningful supplier to Costa Rica, and the relationship is commercial rather than treaty-based, which is worth stating honestly. United Nations COMTRADE data reported via Trading Economics puts India's total exports to Costa Rica at about US$244.64 million in 2025, of which pharmaceutical products under HS Chapter 30 were around US$26.43 million – the third-largest line after vehicles and miscellaneous chemical products. India's Ministry of External Affairs records that Indian exports to Costa Rica consist mainly of chemical products, pharmaceuticals, medical and surgical implements, organic chemicals, rubber and plastics, and that during the first-ever high-level Indian visit to Costa Rica in March 2019 the country was described as keen to benefit from Indian generics, biologicals and biosimilars. There is no India-Costa Rica pharmaceutical or medicines-regulation agreement, and we would rather say that plainly than let a buyer assume a shortcut exists. The file has to stand on its own merits.
Farbe Firma Pvt Ltd works as both manufacturer and CDMO, which suits a market where the same molecule may need to serve a CCSS consolidated purchase, a private hospital and a regional distributor with different pack sizes and different volumes. For Costa Rica we compile CTD-structured dossiers, generate ICH Q1A(R2) and Q1B stability defended on hot and humid conditions, prepare Spanish artwork and inserts for primary and secondary packaging, and supply GMP certificates, certificates of pharmaceutical product, Site Master File, process validation protocols, validated analytical methods with their transfer records, plant and company profiles and per-batch certificates of analysis in a form ready for notarisation and apostille. Where a CCSS ficha tecnica specifies a method that differs from our routine control method, we will run and document the comparison before a sample is submitted rather than after a non-conformity is raised. Flexible batch sizes mean a distributor is not forced to buy tender-scale quantities to serve a private channel, and contract development, own-label supply and technology transfer are all available on the same quality system.
Explore Farbe Firma: Products | Global Reach | About Us
Frequently Asked Questions (FAQ)
Who regulates medicines and injectables in Costa Rica?
The Ministerio de Salud. Registration is filed virtually through the Registrelo platform at registrelo.go.cr, carries a validity of five years, and is governed substantively by the Central American technical regulation RTCA 11.03.59 on sanitary registration requirements for medicines for human use, adopted into Costa Rican law by executive decree, alongside national instruments covering bioequivalence, biological products, therapeutic equivalence and stability studies. Registration resolutions are issued under the Ministry's DRPIS reference. Importers must be registered with the Ministry, and the importing entity is a drogueria.
Does a foreign manufacturer need a local representative in Costa Rica?
In practice, yes. The registration requirements include a legal representative and a responsible professional, each appointed by a power of attorney that must be notarised and apostilled, and the legal representative is a person domiciled in Costa Rica who receives notifications on the holder's behalf. Importation is separately handled by a Ministry-registered drogueria, and each shipment is cleared through the customs single window using the drug import authorisation form. Public procurement runs through the SICOP system, which does publish a registration procedure for foreign suppliers, but the medicines-specific representative and importer requirements sit on top of that, so most foreign manufacturers work through a locally registered representative.
Does Costa Rica recognise registrations granted by other regulators?
Not in the way that is often claimed. Executive Decree 43590-S, which provided for homologation of registrations granted by ICH member authorities, was declared unconstitutional by the Sala Constitucional in judgment 2024-21860 in August 2024, with retroactive effect. What remains is reliance under Decree 39433-S, as reformed, on the evaluation and approval of final reports of clinical and non-clinical studies by recognised reference regulatory authorities, a list the Ministry expanded from nine to thirty-five in November 2023. Separately, the RTCA provides for mutual recognition of sanitary registrations between Central American signatory countries, but each authority still evaluates according to its own national legislation, so a registration elsewhere in the region is not a passport into Costa Rica.
What is CCSS prequalification and why does it matter for injectables?
It is the gate to the public market. The Caja Costarricense de Seguro Social will not purchase a medicine that has not passed its Precalificacion Tecnica de Medicamentos. Appointments are requested by email on Thursdays and notified on Fridays, and the supplier then delivers documentation and a physical product sample to the Laboratorio de Normas y Calidad de Medicamentos, where the sample is tested against the analytical monograph in the CCSS ficha tecnica, the manufacturer's declared specification or the specification the Ministry approved, together with USP and BP general chapters. Up to three non-conformities allow a single ten-working-day correction. More than three, a missed deadline, or any non-conformity requiring a root-cause investigation results in a No Conforme outcome and a restart from zero with a new sample. Decisions are issued within a maximum of fifty-five calendar days.
What makes Farbe Firma a suitable injectable manufacturer for Costa Rica?
Farbe Firma Pvt Ltd is a WHO-GMP certified sterile injectable manufacturer and CDMO in Gujarat, India, filling on ISO Class 5 aseptic lines and exporting to more than 30 countries. For Costa Rica we compile CTD-structured dossiers, generate ICH Q1A(R2) and Q1B stability data defended on hot and humid conditions, work to IP, USP, BP and EP monographs with documented method validation and transfer so that a CCSS laboratory test against USP or BP general chapters is a confirmation rather than a risk, prepare Spanish artwork and inserts in editable form, and issue GMP certificates, certificates of pharmaceutical product, Site Master File, process validation protocols and per-batch certificates of analysis ready for notarisation and apostille. Contact director@farbefirma.org to discuss a specific molecule, tender or own-label programme.
Technically Reviewed By: Maulik Sudani | Jignasu Sudani (Technical Expert)
Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA
Request a Quote | View Products | FAQ | Blog
Comments